About 4 results found for searched term "ML138" (0.122 seconds)
Cat.No. | Name | Target |
---|---|---|
M8453 | ML138 | Others |
ML138 (CID 44601470) is a highly selective agonist at kappa opioid receptors (KOR) that potently activate G protein coupling but weakly interact with β arrestin2. | ||
M10782 | APG-1387 | IAP |
APG-1387 is a divalent SMAC mimetic that is an IAP antagonist that blocks the activity of the IAP family of proteins (XIAP, cIAP-1, cIAP-2, and ML-IAP). APG-1387 induces degradation of cIAP-1 and XIAP proteins as well as caspase-3 activation and PARP lysis, leading to apoptosis. APG-1387 can be used for the study of hepatocellular carcinoma, ovarian cancer and nasopharyngeal carcinoma. | ||
M24888 | Cetrelimab | PD-1/PD-L1 |
JNJ 63723283; JNJ 3283 | ||
Cetrelimab (JNJ 63723283; JNJ 3283) is a humanized IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo. | ||
M40720 | I-138 | Deubiquitinase |
I-138 is an orally active, potent reversible inhibitor of USP1-UAF1, structurally related to ML323, showing synergistic binding to ubiquitin and mutually exclusive binding to ML323. I-138 induces mono-ubiquitination of FANCD2 and PCNA in MDA-MB-436 cells, increases PCNA and FANCD2 mono-ubiquitination in HAP-1 USP1 WT cells, and abrogates USP1 auto-cleavage in cells. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.